Trial Purpose

The purpose of this study is to assess the efficacy and safety of MK-5684 plus hormone replacement therapy (HRT) compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agent (NHA). The primary study hypotheses are that MK-5684 is superior to alternative abiraterone acetate or enzalutamide with respect to radiographic progression free survival (rPFS) per Prostate Cancer Working Group (PCWG) Modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and overall survival (OS), in androgen receptor ligand binding domain (AR LBD) mutation positive and negative participants.

View full trial information on



When speaking to your doctor, please have the trial identifier number available.

About The Trial

Trial Phase Icon

Phase 3

Tests the medicine or vaccine in approximately 1,000 to 5,000 volunteers. For medicines, volunteers have the disease or condition the medicine is designed to treat. In vaccine studies, the volunteers may be healthy or have diseases or conditions. Phase 3 trials take place in hospitals, clinics or physician offices.

Trial start Icon


  • Actual study start date December 18, 2023
  • Estimated primary completion date December 2, 2030
  • Estimated study completion date December 2, 2030


Conditions Icon


Metastatic Castration-resistant Prostate Cancer, Prostatic Neoplasms

Age Range Icon

Age Range

18 - No Age Maximum

Sex Icon



Trial locations